ArticleTherapeutic advances in medical oncology2026
(Neo)adjuvant therapy patterns and outcomes in patients with HR+/HER2+ early breast cancer: a real-world study using the national cancer information database in China.
Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The introduction of pertuzumab in mainland China in 2019 has significantly altered the treatment practice for early breast cancer; however, comprehensive real-world data on hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-positive (HER2+) patients in this new era remain limited. Objective: To identify the clinicopathological characteristics, (neo)adjuvant treatment patterns, and clinical outcomes in treated patients with HR+/HER2+ early breast cancer in routine clinical practice in China. Design: A retrospective, observational study was conducted in patients with HR+/HER2+ early breast cancer who underwent surgery for breast cancer and had post-surgical pathologic reports available. De-identified patient data for this multicenter study were obtained from the National Cancer Information Database (NCID) in China. Methods: Patients were treated with neoadjuvant and adjuvant therapy with chemotherapy and/or HER2-targeted regimens in clinical practice. The main outcomes and measures were as follows: (neo)adjuvant treatment patterns, total pathologic complete responses (tpCR), breast pathologic complete responses (bpCR), disease-free survival (DFS), and event-free survival (EFS). Two-year DFS and EFS were evaluated using the Kaplan-Meier method. Multivariable logistic and Cox regression analyses were performed to identify associated factors of pCR and survival outcomes, respectively. The median duration of follow-up for the study was 13.9 months (range: 0.1-48.1). Results: A total of 13,323 patients with HR+/HER2+ early breast cancer were included in this analysis. Trastuzumab + pertuzumab (TP) was the most commonly used regimen in both neoadjuvant and adjuvant settings. Neoadjuvant therapy with dual HER2 blockade resulted in significantly higher tpCR rates (49.1% vs 29.9%) and bpCR rates (53.3% vs 34.4%) compared with trastuzumab alone (both Conclusion: The dual HER2 blockade regimens that were widely adopted in China for HR+/HER2+ early breast cancer have demonstrated effectiveness in improving pCR in routine clinical practice; a longer follow‑up is required to validate survival outcomes. Trial registration: None.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.